EYEG
Income statement / Annual
Last year (2020), EyeGate Pharmaceuticals, Inc.'s total revenue was $12,059.00,
a decrease of 99.55% from the previous year.
In 2020, EyeGate Pharmaceuticals, Inc.'s net income was -$8.09 M.
See EyeGate Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$12,059.00
|
$2.69 M
|
$1.65 M
|
$407,518.00
|
$669,259.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$12,046.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$13.00 |
$2.69 M |
$1.65 M |
$407,518.00 |
$669,259.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
1 |
1 |
1 |
1 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$3.57 M
|
$5.39 M
|
$8.06 M
|
$10.33 M
|
$8.42 M
|
$2.72 M
|
$531,116.00
|
$1.01 M
|
$3.03 M
|
| General & Administrative
Expenses |
$4.66 M
|
$4.41 M
|
$4.44 M
|
$4.64 M
|
$5.59 M
|
$3.96 M
|
$1.93 M
|
$2.09 M
|
$2.82 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$4.66 M
|
$4.41 M
|
$4.44 M
|
$4.64 M
|
$5.59 M
|
$3.96 M
|
$1.93 M
|
$2.09 M
|
$2.82 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$8.22 M |
$9.80 M |
$12.50 M |
$14.97 M |
$14.02 M |
$6.68 M |
$2.46 M |
$3.10 M |
$5.85 M |
| Cost And Expenses |
$8.22 M |
$9.80 M |
$12.50 M |
$14.97 M |
$14.02 M |
$6.68 M |
$2.46 M |
$3.10 M |
$5.85 M |
| Interest Income |
$23,339.00 |
$108,066.00 |
$120,363.00 |
$564.00 |
$3,684.00 |
$947.00 |
$1,102.00 |
$2,186.00 |
$11,127.00 |
| Interest Expense |
$4,186.00 |
$325.00 |
$1,040.00 |
$1,215.00 |
$275.00 |
$1.93 M |
$441,720.00 |
$611,386.00 |
$0.00 |
| Depreciation &
Amortization |
$33,399.00
|
$213,933.00
|
$38,483.00
|
$19,288.00
|
$5,185.00
|
$1,257.00
|
$1,724.00
|
$5,455.00
|
$9,094.00
|
| EBITDA |
-$8.04 M
|
-$6.79 M
|
-$10.69 M
|
-$14.54 M
|
-$13.34 M
|
-$6.46 M
|
-$1.33 M
|
-$3.26 M
|
-$6.03 M
|
| EBITDA Ratio |
-666.91 |
-2.53 |
-6.47 |
-35.68 |
-19.93 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-681.05
|
-2.65
|
-6.56
|
-35.73
|
-19.94
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$132,870.00
|
$107,741.00
|
$119,323.00
|
-$651.00
|
$3,409.00
|
-$1.71 M
|
$910,575.00
|
-$584,680.00
|
$43,875.00
|
| Income Before Tax |
-$8.08 M |
-$7.00 M |
-$10.73 M |
-$14.56 M |
-$13.34 M |
-$8.39 M |
-$1.55 M |
-$3.68 M |
-$5.81 M |
| Income Before Tax Ratio
|
-670.03
|
-2.61
|
-6.49
|
-35.73
|
-19.94
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$12,055.00 |
$95,396.00 |
$86,045.00 |
-$1.34 M |
$3,684.00 |
$224,129.00 |
$1.35 M |
$26,706.00 |
$43,875.00 |
| Net Income |
-$8.09 M |
-$7.10 M |
-$10.81 M |
-$13.22 M |
-$13.34 M |
-$8.39 M |
-$1.77 M |
-$3.88 M |
-$6.03 M |
| Net Income Ratio |
-671.03 |
-2.64 |
-6.54 |
-32.44 |
-19.94 |
0 |
0 |
0 |
0 |
| EPS |
-2.54 |
-2.23 |
-4.57 |
-13.9 |
-22.66 |
-18.14 |
-3.83 |
-11.62 |
-469.29 |
| EPS Diluted |
-2.54 |
-2.23 |
-4.57 |
-13.9 |
-22.66 |
-18.14 |
-3.83 |
-11.62 |
-469.29 |
| Weighted Average Shares
Out |
$3.18 M
|
$3.18 M
|
$2.37 M
|
$950,678.00
|
$588,929.00
|
$462,747.00
|
$462,747.00
|
$334,001.00
|
$12,858.00
|
| Weighted Average Shares
Out Diluted |
$3.18 M
|
$3.18 M
|
$2.37 M
|
$950,678.00
|
$588,929.00
|
$462,747.00
|
$462,747.00
|
$334,001.00
|
$12,858.00
|
| Link |
|
|
|
|
|
|
|
|
|
